Halozyme Therapeutics Stock Forecast

Stock Price Forecast

The 7 analysts with 12-month price forecasts for Halozyme Therapeutics stock have an average target of 82.29, with a low estimate of 57 and a high estimate of 96. The average target predicts an increase of 9.78% from the current stock price of 74.96.

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$57	$82.29	$90	$96
Change	-23.96%	+9.78%	+20.06%	+28.07%

Analyst Ratings

The average analyst rating for Halozyme Therapeutics stock from 10 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	4	4	4	4	4	4
Buy	2	2	2	2	2	2
Hold	2	2	2	2	3	3
Sell	0	0	0	0	0	0
Strong Sell	1	1	1	1	1	1
Total	9	9	9	9	10	10

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Mitchell Kapoor H.C. Wainwright	H.C. Wainwright	Buy Reiterates $95	Buy	Reiterates	$95	+26.73%	Jun 16, 2026
Corinne Johnson Goldman Sachs	Goldman Sachs	Sell Maintains $57	Sell	Maintains	$57	-23.96%	Jun 15, 2026
Sean Laaman Morgan Stanley	Morgan Stanley	Buy Maintains $93	Buy	Maintains	$93	+24.07%	Jun 15, 2026
Mohit Bansal Wells Fargo	Wells Fargo	Hold Reiterates $75	Hold	Reiterates	$75	+0.05%	Jun 15, 2026
Unknown Analyst J.P. Morgan No rating	J.P. Morgan	Hold Maintains $70	Hold	Maintains	$70	-6.62%	May 20, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

1.78B

from 1.40B

27.27%

from 1.40B

Revenue Next Year

2.00B

from 1.78B

12.47%

from 1.78B

EPS This Year

8.14

from 4.15

96.17%

from 4.15

EPS Next Year

9.89

from 8.14

21.52%

from 8.14

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	443.31M	660.12M	829.25M	1.02B	1.40B	1.78B	2.00B
Revenue Growth	65.66%	48.91%	25.62%	22.44%	37.55%	27.27%	12.47%
EPS	2.74	1.44	2.10	3.43	2.56	6.73	8.74
EPS Growth	201.10%	-47.45%	45.83%	63.33%	-25.36%	162.97%	29.75%
Forward PE	-	-	-	-	-	11.13	8.58
No. Analysts	-	-	-	-	-	9	8

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	1.8B	2.0B
Avg	1.8B	2.0B
Low	1.8B	1.9B

Revenue Growth

Revenue Growth	2026	2027
High	29.7%	15.0%
Avg	27.3%	12.5%
Low	25.4%	8.9%

EPS Forecast

EPS	2026	2027
High	8.21	10.12
Avg	8.14	9.89
Low	8.04	9.49

EPS Growth

EPS Growth	2026	2027
High	97.8%	24.3%
Avg	96.2%	21.5%
Low	93.7%	16.6%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.